Dossier assessment
Luspatercept (transfusion-dependent beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Luspatercept (transfusion-dependent beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Luspatercept (transfusion-dependent beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with anaemia associated with transfusion-dependent beta-thalassaemia
Added benefit not proven
Project details
- Project no.
- A23-43
- Commission
- Commission awarded on 15.05.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Luspatercept (beta-thalassaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Luspatercept (myelodysplastic syndromes) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Luspatercept (myelodysplastic syndrome) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Luspatercept (myelodysplastic syndromes) – Benefit assessment according to § 35a Social Code Book V
Status: Commission completed